Kidney transplantation remains limited by organ shortage, thus increasing focus on improving deceased donor kidney use.1,2 With modern direct-acting antivirals (DAAs), transplantation of kidneys from viremic donors with positive hepatitis C virus nucleic acid testing (HCV-NAT+) represents a major breakthrough with the potential to significantly increase the number of transplants, as kidneys from HCV+ donors were historically at high risk for discard.3-5 Accumulating recent publications have demonstrated the safety and efficacy of HCV-NAT+ deceased donor kidney transplantation in recipients with or without HCV (Table S1).